Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More

Rhythm Secures European Commission Marketing Authorization For Genetic Disease Candidate

The European Commission (EC) has expanded the marketing authorization for Rhythm’s (NASDAQ: RYTM) lead drug product IMCIVREE (setmelanotide) to include the treatment of obesity and control of hunger associated with genetically confirmed Bardet-Biedl syndrome (BBS) in adult and pediatric patients 6 years of age an

RYTM